Advertisement
Table 2 Clinicopathologic characteristics of patients stratified by both neoadjuvant and adjuvant chemotherapy
| Parameters | With preoperative chemotherapy (n = 122) | P value | Without preoperative chemotherapy (n = 142) | P value | ||
|---|---|---|---|---|---|---|
| With ACT (n, %) | Without ACT (n, %) | With ACT (n, %) | Without ACT (n, %) | |||
| Number of patients | 98 | 24 | 102 | 40 | ||
| Age, years | ||||||
| ≤ 60 | 69 (70.4) | 16 (66.7) | 0.721 | 60 (58.8) | 19 (47.5) | 0.222 |
| > 60 | 29 (29.6) | 8 (33.3) | 42 (41.2) | 21 (52.5) | ||
| Sex | ||||||
| Male | 65 (66.3) | 17 (70.8) | 0.673 | 63 (61.8) | 26 (65.0) | 0.720 |
| Female | 33 (33.7) | 7 (29.2) | 39 (38.2) | 14 (35.0) | ||
| Primary tumor location | ||||||
| Colon | 55 (56.1) | 15 (62.5) | 0.571 | 71 (69.6) | 22 (55.0) | 0.100 |
| Rectum | 43 (43.9) | 9 (37.5) | 31 (30.4) | 18 (45.0) | ||
| Primary tumor differentiation | ||||||
| Well to moderate | 72 (73.5) | 20 (83.3) | 0.315 | 83 (81.4) | 31 (77.5) | 0.602 |
| Poor | 26 (26.5) | 4 (16.7) | 19 (18.6) | 9 (22.5) | ||
| T stagea | ||||||
| 1–3 | 50 (53.2) | 12 (54.5) | 0.909 | 72 (77.4) | 23 (67.6) | 0.261 |
| 4 | 44 (46.8) | 10 (45.5) | 21 (22.6) | 11 (32.4) | ||
| N stageb | ||||||
| 0 | 41 (45.6) | 12 (54.5) | 0.449 | 37 (40.2) | 13 (38.2) | 0.840 |
| 1–2 | 49 (54.4) | 10 (45.5) | 55 (59.8) | 21 (61.8) | ||
| Timing of metastasis | ||||||
| Synchronous | 74 (75.5) | 15 (62.5) | 0.198 | 62 (60.8) | 20 (50.0) | 0.242 |
| Metachronous | 24 (24.5) | 9 (37.5) | 40 (39.2) | 20 (50.0) | ||
| Number of metastatic tumors | ||||||
| 1 | 29 (29.6) | 9 (37.5) | 0.453 | 73 (71.6) | 29 (72.5) | 0.912 |
| 2–5 | 69 (70.4) | 15 (62.5) | 29 (28.4) | 11 (27.5) | ||
| Metastases diameter (cm)c | ||||||
| ≤ 3 | 59 (62.1) | 14 (58.3) | 0.735 | 75 (73.5) | 25 (64.1) | 0.270 |
| > 3 | 36 (37.9) | 10 (41.7) | 27 (26.5) | 14 (35.9) | ||
| Preoperative CEA (ng/mL)d | ||||||
| ≤ 50 | 78 (82.1) | 17 (81.0) | 0.901 | 78 (81.3) | 27 (69.2) | 0.128 |
| > 50 | 17 (17.9) | 4 (19.0) | 18 (18.8) | 12 (30.8) | ||
| Preoperative CA19-9 (U/mL)e | ||||||
| ≤ 35 | 70 (76.9) | 15 (75.0) | 1.000 | 58 (61.1) | 23 (62.2) | 0.906 |
| > 35 | 21 (23.1) | 5 (25.0) | 37 (38.9) | 14 (37.8) | ||
| MSKCC-CRSf | ||||||
| 0–2 | 54 (63.5) | 9 (47.4) | 0.193 | 73 (83.0) | 26 (78.8) | 0.597 |
| 3–5 | 31 (36.5) | 10 (52.6) | 15 (17.0) | 7 (21.2) | ||
| Preoperative chemotherapy regimen | ||||||
| FOLFOX + XELOX | 61 (62.2) | 18 (75.0) | 0.503 | |||
| FOLFIRI | 31 (31.6) | 5 (20.8) | ||||
| Capecitabine | 6 (6.1) | 1 (4.2) | ||||
| Radiological response to preoperative chemotherapyg | ||||||
| PR | 57 (58.8) | 13 (54.2) | 0.683 | |||
| SD | 30 (30.9) | 7 (29.2) | ||||
| PD | 10 (10.3) | 4 (16.7) | ||||
